Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

DL. Bhatt, JW. Eikelboom, SJ. Connolly, PG. Steg, SS. Anand, S. Verma, KRH. Branch, J. Probstfield, J. Bosch, O. Shestakovska, M. Szarek, AP. Maggioni, P. Widimský, A. Avezum, R. Diaz, BS. Lewis, SD. Berkowitz, KAA. Fox, L. Ryden, S. Yusuf,...

. 2020 ; 141 (23) : 1841-1854. [pub] 20200328

Language English Country United States

Document type Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026682

BACKGROUND: Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events. METHODS: In a prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse limb events, including amputation). The primary safety end point was a modification of the International Society on Thrombosis and Haemostasis criteria for major bleeding. RESULTS: There were 10 341 patients with diabetes mellitus and 17 054 without diabetes mellitus in the overall trial. A consistent and similar relative risk reduction was seen for benefit of rivaroxaban plus aspirin (n=9152) versus placebo plus aspirin (n=9126) in patients both with (n=6922) and without (n=11 356) diabetes mellitus for the primary efficacy end point (hazard ratio, 0.74, P=0.002; and hazard ratio, 0.77, P=0.005, respectively, Pinteraction=0.77) and all-cause mortality (hazard ratio, 0.81, P=0.05; and hazard ratio, 0.84, P=0.09, respectively; Pinteraction=0.82). However, although the absolute risk reductions appeared numerically larger in patients with versus without diabetes mellitus, both subgroups derived similar benefit (2.3% versus 1.4% for the primary efficacy end point at 3 years, Gail-Simon qualitative Pinteraction<0.0001; 1.9% versus 0.6% for all-cause mortality, Pinteraction=0.02; 2.7% versus 1.7% for major vascular events, Pinteraction<0.0001). Because the bleeding hazards were similar among patients with and without diabetes mellitus, the prespecified net benefit for rivaroxaban appeared particularly favorable in the patients with diabetes mellitus (2.7% versus 1.0%; Gail-Simon qualitative Pinteraction=0.001). CONCLUSIONS: In stable atherosclerosis, the combination of aspirin plus rivaroxaban 2.5 mg twice daily provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral end points in patients with and without diabetes mellitus. Given their higher baseline risk, the absolute benefits appeared larger in those with diabetes mellitus, including a 3-fold greater reduction in all-cause mortality. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026682
003      
CZ-PrNML
005      
20211026132711.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCULATIONAHA.120.046448 $2 doi
035    __
$a (PubMed)32223318
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bhatt, Deepak L $u Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School Boston, MA (D.L.B.)
245    10
$a Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial / $c DL. Bhatt, JW. Eikelboom, SJ. Connolly, PG. Steg, SS. Anand, S. Verma, KRH. Branch, J. Probstfield, J. Bosch, O. Shestakovska, M. Szarek, AP. Maggioni, P. Widimský, A. Avezum, R. Diaz, BS. Lewis, SD. Berkowitz, KAA. Fox, L. Ryden, S. Yusuf, COMPASS Steering Committee and Investigators
520    9_
$a BACKGROUND: Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events. METHODS: In a prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse limb events, including amputation). The primary safety end point was a modification of the International Society on Thrombosis and Haemostasis criteria for major bleeding. RESULTS: There were 10 341 patients with diabetes mellitus and 17 054 without diabetes mellitus in the overall trial. A consistent and similar relative risk reduction was seen for benefit of rivaroxaban plus aspirin (n=9152) versus placebo plus aspirin (n=9126) in patients both with (n=6922) and without (n=11 356) diabetes mellitus for the primary efficacy end point (hazard ratio, 0.74, P=0.002; and hazard ratio, 0.77, P=0.005, respectively, Pinteraction=0.77) and all-cause mortality (hazard ratio, 0.81, P=0.05; and hazard ratio, 0.84, P=0.09, respectively; Pinteraction=0.82). However, although the absolute risk reductions appeared numerically larger in patients with versus without diabetes mellitus, both subgroups derived similar benefit (2.3% versus 1.4% for the primary efficacy end point at 3 years, Gail-Simon qualitative Pinteraction<0.0001; 1.9% versus 0.6% for all-cause mortality, Pinteraction=0.02; 2.7% versus 1.7% for major vascular events, Pinteraction<0.0001). Because the bleeding hazards were similar among patients with and without diabetes mellitus, the prespecified net benefit for rivaroxaban appeared particularly favorable in the patients with diabetes mellitus (2.7% versus 1.0%; Gail-Simon qualitative Pinteraction=0.001). CONCLUSIONS: In stable atherosclerosis, the combination of aspirin plus rivaroxaban 2.5 mg twice daily provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral end points in patients with and without diabetes mellitus. Given their higher baseline risk, the absolute benefits appeared larger in those with diabetes mellitus, including a 3-fold greater reduction in all-cause mortality. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x aplikace a dávkování $7 D000925
650    _2
$a Aspirin $x aplikace a dávkování $7 D001241
650    _2
$a kardiovaskulární nemoci $x krev $x farmakoterapie $x epidemiologie $7 D002318
650    _2
$a diabetes mellitus $x krev $x farmakoterapie $x epidemiologie $7 D003920
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a inhibitory faktoru Xa $7 D065427
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $7 D010975
650    _2
$a rivaroxaban $x aplikace a dávkování $7 D000069552
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Eikelboom, John W $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (J.W.E., S.J.C., S.S.A., J.B., O.S., S.Y.)
700    1_
$a Connolly, Stuart J $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (J.W.E., S.J.C., S.S.A., J.B., O.S., S.Y.)
700    1_
$a Steg, P Gabriel $u Université de Paris and Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France (P.G.S.)
700    1_
$a Anand, Sonia S $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (J.W.E., S.J.C., S.S.A., J.B., O.S., S.Y.)
700    1_
$a Verma, Subodh $u Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Ontario, Canada (S.V.)
700    1_
$a Branch, Kelley R H $u University of Washington Medical Centre, Seattle (K.R.H.B., J.P.)
700    1_
$a Probstfield, Jeffrey $u University of Washington Medical Centre, Seattle (K.R.H.B., J.P.)
700    1_
$a Bosch, Jackie $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (J.W.E., S.J.C., S.S.A., J.B., O.S., S.Y.) $u School of Rehabilitation Science, Mc-Master University, Hamilton, Ontario, Canada (J.B.)
700    1_
$a Shestakovska, Olga $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (J.W.E., S.J.C., S.S.A., J.B., O.S., S.Y.)
700    1_
$a Szarek, Michael $u State University of New York, Downstate School of Public Health, Brooklyn (M.S.)
700    1_
$a Maggioni, Aldo Pietro $u ANMCO Research Center, Florence, Italy (A.P.M.)
700    1_
$a Widimský, Petr $u Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic (P.W.)
700    1_
$a Avezum, Alvaro $u Hospital Alemão Oswaldo Cruz, São Paulo, Brazil (A.A.)
700    1_
$a Diaz, Rafael $u Estudios Clínicos Latino América, Rosario, Argentina (R.D.) $u Instituto Cardiovascular de Rosario, Argentina (R.D.)
700    1_
$a Lewis, Basil S $u Lady Davis Carmel Medical Centre and the Technion-Israel Institute of Technology, Haifa (B.S.L.)
700    1_
$a Berkowitz, Scott D $u Bayer US LLC, Whippany, NJ (S.D.B.)
700    1_
$a Fox, Keith A A $u Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (K.A.A.F.)
700    1_
$a Ryden, Lars $u Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden (L.R.)
700    1_
$a Yusuf, Salim $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (J.W.E., S.J.C., S.S.A., J.B., O.S., S.Y.)
710    2_
$a COMPASS Steering Committee and Investigators
773    0_
$w MED00001091 $t Circulation $x 1524-4539 $g Roč. 141, č. 23 (2020), s. 1841-1854
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32223318 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132717 $b ABA008
999    __
$a ok $b bmc $g 1715426 $s 1147189
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 141 $c 23 $d 1841-1854 $e 20200328 $i 1524-4539 $m Circulation (New York, N.Y.) $n Circulation (New York) $x MED00001091
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options